Pharmacogenetics-based area-under-curve model can predict efficacy and adverse events from axitinib in individual patients with advanced renal cell carcinoma

Yoshiaki Yamamoto
Ryouichi Tsunedomi
Yusuke Fujita
Toru Otori
Mitsuyoshi Ohba
Yoshihisa Kawai
Hiroshi Hirata
Hiroaki Matsumoto
Jun Haginaka
Shigeo Suzuki
Rajvir Dahiya
Yoshihiko Hamamoto
Kenji Matsuyama
Shoichi Hazama
Hiroaki Nagano
Hideyasu Matsuyama

Oncotarget

Impact Journals LLC

9

24

17160

17170

10.18632/oncotarget.24715

https://doi.org/10.18632/oncotarget.24715
https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85044784293&origin=inward
https://www.scopus.com/inward/citedby.uri?partnerID=HzOxMe3b&scp=85044784293&origin=inward